12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zytiga abiraterone acetate regulatory update

The Scottish Medicines Consortium recommended the restricted use of Johnson & Johnson's Zytiga abiraterone acetate on the National Health Service (NHS) in Scotland in combination with prednisone or prednisolone in patients with metastatic, castration-resistant prostate cancer (CRPC) that has progressed on or after docetaxel-based chemotherapy - the drug's approved indication. Following a resubmission from the company, the consortium recommended the use of Zytiga...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >